Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo

Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline

Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix

Topline data from ORCA-1 trial expected in the Second Quarter of 2019

Topline data from ORCA-1 trial expected in the Second Quarter of 2019

Topline data from ORCA-1 trial expected in mid-2019

Cytisine Demonstrated Superior Abstinence Rates Compared to Nicotine Replacement Therapy

Company invites individual and institutional investors and advisors to attend virtualinvestorconferences.com

Rapid Progress on Advancing Clinical Program with Commencement of Pharmacokinetic (PK) & Pharmacodynamic (PD) Cytisine Study and Completion of Enrollment in Food Effect PK Study

Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017

Professor Nancy Rigotti, MD, will chair a symposium entitled "Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication"

Ongoing IND-enabling Non-clinical Program to Support the Use of Cytisine in Smoking Cessation

Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation